AC Immune SA
ACIU
查看详细走势图
3.180USD
+0.150+4.95%
收盘 12/22, 16:00（美东）报价延迟15分钟
319.30M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.95%
5天
-1.85%
1月
+6.00%
6月
+69.15%
今年开始到现在
+17.78%
1年
+18.66%
查看详细走势图
TradingKey AC Immune SA股票评分
单位: USD 更新时间: 2025-12-22操作建议
AC Immune SA当前公司基本面数据相对稳定，增长潜力稳定。当前估值合理，在生物技术与医疗研究行业排名156/404位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价9.00。中期看，股价处于上升通道。近一个月，市场表现一般，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
AC Immune SA评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
强力买入
评级
9.000
目标均价
+223.74%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
AC Immune SA亮点
亮点风险
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
业绩高增长
公司营业收入稳步增长，连续3年增长631.15%
业绩增长期
公司处于发展阶段，最新年度总收入30.97M美元
估值合理
公司最新PE估值-3.54，处于3年历史合理位
机构加仓
最新机构持股24.95M股，环比增加0.03%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值4.76K
AC Immune SA新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
AC Immune SA简介
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
公司代码ACIU
公司AC Immune SA
CEOPfeifer (Andrea)
网址https://www.acimmune.com/
常见问题
AC Immune SA(ACIU)的当前股价是多少？
AC Immune SA(ACIU)的当前股价是 3.180。
AC Immune SA的股票代码是什么？
AC Immune SA的股票代码是ACIU。
AC Immune SA股票的52周最高点是多少？
AC Immune SA股票的52周最高点是4.000。
AC Immune SA股票的52周最低点是多少？
AC Immune SA股票的52周最低点是1.430。
AC Immune SA的市值是多少？
AC Immune SA的市值是319.30M。
AC Immune SA的净利润是多少？
AC Immune SA的净利润为-50.92M。
现在AC Immune SA(ACIU)的股票是买入、持有还是卖出？
根据分析师评级，AC Immune SA(ACIU)的总体评级为--，目标价格为9.000。
AC Immune SA(ACIU)股票的每股收益（EPS TTM）是多少
AC Immune SA(ACIU)股票的每股收益（EPS TTM）是-0.898。
相关品种
